|
|
|
|
||
Re: Biotech2k pretty negative now on acadAttacking a fellow investor is not my thing, but I would remind everyone here that Biotech2k recommended Incyte when it was around $80. The day after his recommendation, INCY fell to the $60s on bad news. Re: his comments on ACAD, the rebuttal is easy and could be made by any grade-schooler. If Nuplazid were not as efficacious as Acadia claims, if the company somehow fudged the MDD numbers, then how do you explain the following? 1. Dr. Paul Andreason, the FDA's devil's advocate during the Advisory Committee hearing and the source of CNN's silly attack piece, conceded right at the start of the AdCom that there were no grounds for contesting the Phase 3 020 trial on efficacy. Even he admitted the drug works. 2. Every respected expert who has looked at Nuplazid over the last 6 or more years is on record saying Nuplazid is an effective treatment for psychosis in general and for PDP in particular. 3. Numerous patients have posted positive testimonials online. 4. Maurizio Fava, professor at Harvard Medical School, had this comment about the MDD trial: “The results of this study suggest pimavanserin may represent a novel approach to adjunctive treatment for patients suffering from major depressive disorder." 5. Nuplazid's been shown to be effective in the clinic for 4 neuropsych conditions: schizophrenia, PDP, ADP, and MDD. Even if the MDD numbers were fudged (an outlandish charge), how does somebody explain the positive data in all the other trials? 6. A drug that doesn't work doesn't see $225 million in yearly sales and over $350 million over two years. A drug that doesn't work sees sales like Belviq's or Afrezza's. Defense rests. |
return to message board, top of board |